REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$553.24

Market cap

$59.17B

P/E Ratio

9.39

Dividend/share

N/A

EPS

$58.89

Enterprise value

$59.8B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The company's EPS has surged by 116% YoY and by 57% QoQ
Regeneron Pharmaceuticals's net income has surged by 108% YoY and by 55% QoQ
The debt has increased by 22% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.regeneron.com/
Peers: AMGN ALNY BIIB JNJ

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
106.96M
Market cap
$59.17B
Enterprise value
$59.8B
Valuations
Price to earnings (P/E)
9.39
Price to book (P/B)
3.9
Price to sales (P/S)
4.69
EV/EBIT
8.19
EV/EBITDA
7.91
EV/Sales
4.83
Earnings
Revenue
$12.38B
EBIT
$7.3B
EBITDA
$7.56B
Free cash flow
$1.69B
Per share
EPS
$58.89
Free cash flow per share
$16.13
Book value per share
$141.98
Revenue per share
$117.94
TBVPS
$204.63
Balance sheet
Total assets
$21.49B
Total liabilities
$6.36B
Debt
$2.7B
Equity
$15.13B
Working capital
$9.61B
Liquidity
Debt to equity
0.18
Current ratio
3.57
Quick ratio
2.92
Net debt/EBITDA
0.08
Margins
EBITDA margin
61%
Gross margin
86.8%
Net margin
50.1%
Operating margin
53.9%
Efficiency
Return on assets
34.2%
Return on equity
51.4%
Return on invested capital
45.6%
Return on capital employed
41.1%
Return on sales
58.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.43%
1 week
0.59%
1 month
-15.15%
1 year
-5.46%
YTD
14.52%
QTD
-8.58%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$12.38B
Gross profit
$10.76B
Operating income
$6.68B
Net income
$6.21B
Gross margin
86.8%
Net margin
50.1%
The operating income has soared by 141% YoY and by 67% QoQ
Regeneron Pharmaceuticals's net income has surged by 108% YoY and by 55% QoQ
The revenue has soared by 68% YoY and by 35% QoQ
Regeneron Pharmaceuticals's gross profit has soared by 67% YoY and by 35% from the previous quarter

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
9.39
P/B
3.9
P/S
4.69
EV/EBIT
8.19
EV/EBITDA
7.91
EV/Sales
4.83
The company's EPS has surged by 116% YoY and by 57% QoQ
REGN's price to earnings (P/E) is 61% lower than its 5-year quarterly average of 24.2 and 33% lower than its last 4 quarters average of 14.0
The equity has surged by 67% year-on-year and by 26% since the previous quarter
REGN's price to book (P/B) is 32% less than its 5-year quarterly average of 5.7 and 17% less than its last 4 quarters average of 4.7
The revenue has soared by 68% YoY and by 35% QoQ
The P/S is 35% lower than the 5-year quarterly average of 7.2 and 21% lower than the last 4 quarters average of 5.9

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has surged by 84% YoY and by 35% QoQ
The return on assets has surged by 68% year-on-year and by 40% since the previous quarter
Regeneron Pharmaceuticals's return on invested capital has surged by 62% YoY and by 45% QoQ
The company's return on sales rose by 33% YoY and by 21% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The quick ratio has soared by 81% YoY and by 22% from the previous quarter
The current ratio has soared by 68% YoY and by 14% QoQ
The debt is 82% less than the equity
The equity has surged by 67% year-on-year and by 26% since the previous quarter
REGN's debt to equity is down by 25% YoY and by 22% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.